GlobeNewswire

XBiotech Announces Dr. Alice Gottlieb to Chair Upcoming Phase 2 Study of Bermekimab in Hidradenitis Suppurativa

Share

AUSTIN, Texas, June 25, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announces that Alice Gottlieb M.D., Ph.D., will Chair the Company’s upcoming Phase II study in Hidradenitis Suppurativa (HS). Dr. Gottlieb is Medical Director of dermatology at the Mount Sinai Beth Israel Campus, and Clinical Professor at the Icahn School of Medicine at Mount Sinai. She is one of few doctors in the nation board certified in Dermatology, Rheumatology and Internal Medicine. This will be the second study Chaired by Dr. Gottlieb involving bermekimab in HS and the third study conducted for the drug in HS.

Dr. Gottlieb received an M.D.-Ph.D. from The Rockefeller University-Cornell University Medical College. Dr. Gottlieb founded the Tufts Dermatology residency program (which formally was shared with Boston University) and served as Chair of Dermatology and Dermatologist-in-Chief of Tufts Medical Center. She also founded the Dermatology Division at UMDNJ-Robert Wood Johnson Medical School where she served as Professor of Medicine, Director of the Clinical Research Center and Founding Director of the Psoriasis Center of Excellence. Before joining the Mount Sinai faculty, she was a Professor of Dermatology at New York Medical College. She is the founder and President of the International Dermatology Outcome Measures (IDEOM) group. Founded in 2013, this 501c3 non-profit, consortium of patients, physicians, pharmaceutical scientists and other stakeholders is dedicated to bringing outcome measures to dermatologic clinical research and practice that satisfy the needs of all stakeholders.

Dr. Gottlieb is internationally recognized for her pioneering work using targeted biological therapies, which helped lead the way for FDA-approvals. Dr. Gottlieb has authored over 400 manuscripts in leading scientific journals, such as The Lancet and The New England Journal of Medicine and has presented her groundbreaking research at hundreds of dermatology and rheumatology conferences around the world. On June 7, 2018 she was honored by an award from the National Psoriasis Foundation for her leadership in psoriasis and psoriatic arthritis research and care.

Dr. Gottlieb commented, “We need more effective treatments for hidradenitis suppurativa. Bermekimab offers the potential option for a more effective treatment for HS.”

XBiotech’s President & CEO, John Simard, commented, “We are honored to have Dr. Gottlieb continue to advance our bermekimab program in HS.”

Dr. Gottlieb chaired a recent open label study with bermekimab that demonstrated that weekly treatment with bermekimab was associated with statistically significant improvement in HS, as measured by the Hidradenitis Suppurativa Clinical Response score (HiSCR). In the study, 61% of patients with no prior biological therapy achieved positive HiSCR at 12 weeks, while 63% of patients who had failed previous biological therapy also achieved a positive HiSCR. HS is associated with severe pain and thus pain was a key measure in the study. At the study’s endpoint, patients with no prior biological therapy had a 64% reduction in pain compared with baseline, while those who had previously failed anti-TNF therapy had a 54% reduction in pain.

Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin disorder affecting areas rich in apocrine glands. Nodules appear in the affected areas and progressively become swollen with spontaneous rupture and release of pus. This process occurs repeatedly leading to formation of deep sinus tracts and painful dermal abscesses. Pain is a paramount condition in patients suffering from HS, as this chronic inflammation and accompanying pain account for the fact that HS is ranked first among skin disorders in terms of adversely affecting quality of life. The global prevalence of HS is estimated at up to 4% of the population.

About True Human™ Therapeutic Antibodies
XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Cable Onda Financial Update18.10.2019 08:45:00 CESTPress release

Cable Onda Financial Update Luxembourg, 18 October 2019 – Millicom announced today that its subsidiary, Cable Onda S.A. (“Cable Onda”), a leading provider of Mobile, Pay TV, fixed broadband, internet and telephony services in both the residential and B2B sectors in Panama, has mandated Goldman Sachs & Co. LLC and J.P. Morgan as Global Coordinators, and BNP Paribas, Morgan Stanley and Scotiabank as Joint Bookrunners for a potential benchmark senior unsecured 144A/RegS USD bond transaction, subject to market conditions. In relation with this planned transaction, Cable Onda informs the market that it expects revenue of approximately $313.0 million to $315.0 million and EBITDA of approximately $149.0 million to $151.0 million on a consolidated basis for the nine months ended September 30, 2019. Cable Onda’s actual operating results remain subject to the completion of its quarter-end closing process, which includes review by management and its board of directors. These expected nine-month r

Orange Belgium invites investors and analysts to participate to its Q3 results conference call on October 23, 201918.10.2019 08:37:00 CESTPress release

Orange Belgium will publish its results for the third quarter of 2019 on Wednesday, October 23 at 07:00 CET. Orange Belgium Investor Relations is pleased to invite investors and analysts to participate in a conference call hosted by: Michaël Trabbia, CEO Arnaud Castille, CFO Eric Chang, Investor Relations The conference call will start at 10:00 am CET (9:00 am UK / 4:00 am EST). To access the call, please dial one of the following numbers 5-10 minutes prior to the start of the conference call in order to avoid waiting time. Consequently register with following pin code: 28900648# and provide your name and the company you work for. Belgium +32 24035816 Canada +1 4162164194 France +33 170710159 Germany +49 69222225429 Ireland +353 15060451 Italy +39 0236013817 Luxembourg +352 27300163 Netherlands +31 207095119 Spain +34 911140101 Switzerland +41 445831805 United Kingdom +44 2071943759 United States +1 6467224916 The recorded session will be available after the conference call and can be

Schibsted ASA (SCHA/SCHB) - Invitation to the presentation of Q3 2019 Results18.10.2019 08:30:00 CESTPress release

We hereby invite you to participate at the presentation of the Q3 2019 reports of Schibsted Media Group on 25 October 2019 Quarterly Earnings Release Time: 25 October 2019 at 07.00 CET Interim report, presentation materials, and spreadsheet with key figures and analytical information will be made available on the investor relations pages at https://www.schibsted.com/ir/. Results Presentation Time: October 2019 at 09.00 CET Location: Schibsted’s premises in Akersgata 55, Oslo, Norway. The presentation will be webcasted live at https://www.schibsted.com/ir/. It will be presented in English. Participants can send in written questions through the webcast player. CEO Kristin Skogen Lund and EVP CFO Trond Berger will present. A recording of the presentation will be available on our web site shortly after the live webcast has ended. Conference call for investors and analysts - Q&A session Time: 25 October 2019 at 14.00 CET Questions relating to the results will be answered in a conference cal

Hofseth Biocare ASA: ENTERS INTO A CONSULTANCY AGREEMENT WITH JAMES BERGER – CONTEMPLATED US LISTING18.10.2019 08:05:00 CESTPress release

Hofseth BioCare ASA ("HBC") has today entered into a consultancy agreement with James Berger (through his company Nevera AG). Mr. Berger is a dual British and Italian citizen currently residing in Switzerland who has previously worked as an investment banker with Goldman Sachs International (London), JP Morgan (London), MAN Investments PLC and Millennium Capital Management LLC. He has a broad network with the largest investment banks and institutional investors in Europe and globally. Mr. Berger has already successfully assisted HBC with its oversubscribed private placement of NOK 118 million that was directed towards international private investors and institutional funds. He has recently also facilitated the sale of additional shares in HBC from certain existing shareholders to new international investors. Under the consultancy agreement, Mr. Berger will assist HBC with certain intermediary services, in establishing a wider base of international investors. Mr. Berger and HBC believe

Yara announces share buy-backs18.10.2019 08:02:00 CESTPress release

Oslo, 18 October 2019: Yara International ASA plans to buy back 0.5% of its outstanding shares by the end of 2019. Including the proportional redemption of shares owned by the Norwegian state, the total buyback and redemption will amount to approximately 0.8% of shares outstanding, equivalent to approximately NOK 800 million at today’s share price. Yara's targeted capital structure is a mid- to long-term Net debt/EBITDA range of 1.5-2.0 and a net debt/equity ratio below 0.60. Subject to these requirements, Yara's ordinary dividend shall be 50% of net income. Shareholder returns are distributed primarily as cash, with share buy-backs as a supplemental lever. Yara’s net debt/EBITDA as of 30 September 2019 would be close to 2.0 including the full effect of the announced buyback. The buy-backs are part of a program authorized by the Annual General meeting held 7 May 2019, which authorized Yara to buy back up to 5% (13,620,131 shares) of its share capital before its 2020 Annual General Meet

Yara med høyere resultat, operasjonell og kommersiell forbedring18.10.2019 08:00:00 CESTPressemelding

Oslo, 18. oktober 2019: Nettoresultat etter minoritetsinteresser for tredje kvartal var på USD 74 millioner (USD 0,27 per aksje), mot USD 98 millioner (USD 0,36 per aksje) for samme periode i fjor. Korrigert for valutaeffekter og spesielle poster var resultatet på USD 0,94 per aksje, mot USD 0,50 per aksje i tredje kvartal 2018. EBITDA eksklusive spesielle poster for tredje kvartal var på USD 630 millioner, opp fra USD 402 millioner ett år tidligere, og reflekterer høyere nitrogen oppgraderingsmarginer og sterke premium-leveranser. «Yara leverer betydelig bedre resultater i andre kvartal, med EBITDA eksklusive spesielle poster og IFRS 16 opp 49 %. Resultatet reflekterer lavere energikostnader, høyere produksjon og sterke premium-leveranser» sier Svein Tore Holsether, konsernsjef i Yara. «Jeg er fornøyd med at vi leverer resultatforbedring innen alle forretningsområder, med sterkest økning i New Business. Yaras avkastning fortsetter å øke, og hovedprioriteten fremover vil fortsatt være